MWVC
ADMS

Morgens Waterfall Vintiadis & Co’s Adamas Pharmaceuticals ADMS Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-69,500
Closed -$1.63M – 70
2018
Q2 		$1.79M Buy
69,500
+32,500
+88% +$900K 1.27% 26
2018
Q1 		$884K Hold
37,000
– – 0.67% 39
2017
Q4 		$1.25M Buy
+37,000
New +$1.03M 0.99% 30

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's ADMS Position: Q3 2018 in Review

Morgens Waterfall Vintiadis & Co sold out of Adamas Pharmaceuticals (ADMS) in Q3 2018, closing a stake of 69,500 shares — an estimated $1.63M sold.

Morgens Waterfall Vintiadis & Co first reported a position in ADMS in Q4 2017 and held it in 3 quarters. The position peaked at $1.79M in Q2 2018. 125 funds tracked by Wall St. Rank hold ADMS as of Q3 2018.

  • Morgens Waterfall Vintiadis & Co reported no remaining Adamas Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 69,500 Adamas Pharmaceuticals shares in Q3 2018, an estimated $1.63M.
  • Morgens Waterfall Vintiadis & Co first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Morgens Waterfall Vintiadis & Co's Adamas Pharmaceuticals position peaked at $1.79M in Q2 2018.
  • 125 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2018.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.